Product description

Icatibant Acetate is a selective competitive antagonist for the bradykinin B2 receptor. It is indicated for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare disorder resulting in periodic attacks of acute edema. It is characterized by a deficiency of functional C1 esterase inhibitor that leads to the overproduction of bradykinin, which triggers vasodilation, vascular permeability, and edema. Icatibant Acetate inhibits bradykinin from binding to the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.
Read more

Specifications

CAS Registry Number 130308-48-4
Categories APIs (Active Pharmaceutical Ingredients); Contract Services - Contract ServicesContract Manufacturing; APIs (Active Pharmaceutical Ingredients)Peptides
Sales markets Middle East Region (e.g. UAE); North America (USA, Canada); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied from Switzerland; United States

More products from Bachem AG

View all our products (24)
Metrochem API Private Limited

Metrochem API Private Limited

Jiudian Pharmaceutical welcome your communication!

Jiudian Pharmaceutical welcome your communication!

PROMOTE A HEALTHIER LIFE FOR HUMANKIND THROUGH ADVANCEMENTS IN SCIENCE

PROMOTE A HEALTHIER LIFE FOR HUMANKIND THROUGH ADVANCEMENTS IN...

Tjoapack

Tjoapack

Discover The Difference of BD Solutions at Hospital, at Outpatient Clinic and at Home

Discover "The Difference" of BD Solutions at Hospital, at Outp...